Didier Jean

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/394240/publications.pdf

Version: 2024-02-01

56	2,113	279701	254106
papers	citations	23	43
		h-index	g-index

62	62	62	2638
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO Journal, 1998, 17, 4358-4369.	3.5	224
2	CREB and Its Associated Proteins Act as Survival Factors for Human Melanoma Cells. Journal of Biological Chemistry, 1998, 273, 24884-24890.	1.6	147
3	Loss of AP-2 Results in Up-regulation ofMCAM/MUC18 and an Increase in Tumor Growth and Metastasis of Human Melanoma Cells. Journal of Biological Chemistry, 1998, 273, 16501-16508.	1.6	141
4	Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nature Communications, 2019, 10, 1333.	5.8	125
5	Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2014, 20, 1323-1334.	3.2	121
6	Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene, 1997, 15, 2069-2075.	2.6	118
7	Molecular Changes in Mesothelioma With an Impact on Prognosis and Treatment. Archives of Pathology and Laboratory Medicine, 2012, 136, 277-293.	1.2	87
8	Inhibition of Tumorigenicity and Metastasis of Human Melanoma Cells by Anti-Cathepsin L Single Chain Variable Fragment. Cancer Research, 2004, 64, 146-151.	0.4	86
9	Genetic alterations of malignant pleural mesothelioma: associationÂwith tumor heterogeneity and overall survival. Molecular Oncology, 2020, 14, 1207-1223.	2.1	74
10	Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene, 2000, 19, 2721-2730.	2.6	68
11	Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene, 2014, 33, 3748-3752.	2.6	68
12	Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma. Clinical Cancer Research, 2017, 23, 3191-3202.	3.2	67
13	Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. , 2000, 212, 19-28.		66
14	Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma. American Journal of Pathology, 2011, 178, 881-894.	1.9	48
15	Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus. Journal of Thoracic Oncology, 2020, 15, 827-842.	0.5	44
16	Downâ€regulation of the expression of RB18A/MED1, a cofactor of transcription, triggers strong tumorigenic phenotype of human melanoma cells. International Journal of Cancer, 2009, 124, 2597-2606.	2.3	43
17	Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. Biochemical Journal, 2002, 361, 173-184.	1.7	41
18	Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2016, 19, 151-172.	2.9	41

#	Article	IF	Citations
19	Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Mutagenesis, 2013, 28, 323-331.	1.0	35
20	Cloning and characterization of anti-cathepsin L single chain variable fragment whose expression inhibits procathepsin L secretion in human melanoma cells. Biochemical Journal, 2002, 367, 219-227.	1.7	34
21	Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma. , 2020, 8, e000182.		32
22	Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Medicine, 2021, 13, 113.	3.6	31
23	Identification on melanoma cells of p39, a cysteine proteinase that cleaves C3, the third component of complement: amino-acid-sequence identities with procathepsin L. Biochemical Journal, 1995, 312, 961-969.	1.7	28
24	Targeting the ATF-1/CREB Transcription Factors by Single Chain Fv Fragment in Human Melanoma: Potential Modality for Cancer Therapy. Critical Reviews in Immunology, 2001, 21, 12.	1.0	28
25	Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms. Oncogene, 2006, 25, 1474-1484.	2.6	27
26	The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models. Frontiers in Oncology, 2020, 10, 388.	1.3	25
27	Modulating BAP1 expression affects ROS homeostasis, cell motility and mitochondrial function. Oncotarget, 2017, 8, 72513-72527.	0.8	24
28	Cathepsin L expression is up-regulated by hypoxia in human melanoma cells: role of its 5â€²-untranslated region. Biochemical Journal, 2008, 413, 125-134.	1.7	23
29	Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells. Cancer Gene Therapy, 2008, 15, 591-604.	2.2	21
30	Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. , 2000, , 19-28.		21
31	Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. Biochemical Journal, 2002, 361, 173.	1.7	20
32	Combined MEK and PI3K/p110Î² Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer Research, 2020, 80, 843-856.	0.4	19
33	Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma. Lung Cancer, 2018, 126, 15-24.	0.9	13
34	Co-expression and secretion of C3, the third component of complement and a C3-cleaving cysteine proteinase in a highly metastatic human melanoma cell line. Immunology Letters, 1997, 58, 107-112.	1.1	12
35	KRAS signaling in malignant pleural mesothelioma. EMBO Molecular Medicine, 2022, 14, e13631.	3.3	12
36	Activation of Epsteinâ€“Barr virus/C3d receptor (gp140, CR2, CD21) on human B lymphoma cell surface triggers Cbl tyrosine phosphorylation, its association with p85 subunit, Crk-L and Syk and its dissociation with Vav. Cellular Signalling, 2006, 18, 1219-1225.	1.7	11

#	Article	IF	Citations
37	Mesotheliomas in Genetically Engineered Mice Unravel Mechanism of Mesothelial Carcinogenesis. International Journal of Molecular Sciences, 2018, 19, 2191.	1.8	10
38	Causes and pathophysiology of malignant pleural mesothelioma. Lung Cancer Management, 2015, 4, 219-229.	1.5	9
39	Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis. Molecular Cancer, 2018, 17, 148.	7.9	8
40	Unraveling the cellular heterogeneity of malignant pleural mesothelioma through a deconvolution approach. Molecular and Cellular Oncology, 2019, 6, 1610322.	0.3	8
41	Infection of human B lymphoma cells byMycoplasma fermentansinduces interaction of its elongation factor with the intracytoplasmic domain of Epstein-Barr virus receptor (gp140, EBV/C3dR, CR2, CD21). FEMS Microbiology Letters, 2005, 249, 359-366.	0.7	5
42	Biomolecular Pathways and Malignant Pleural Mesothelioma. , 2016, , 169-192.		4
43	A Community-Driven, Openly Accessible Molecular Pathway Integrating Knowledge on Malignant Pleural Mesothelioma. Frontiers in Oncology, 2022, 12, 849640.	1.3	4
44	Construction and expression of intracellular anti-ATF-1 single chain Fv fragment: a modality to inhibit melanoma tumor growth and metastasis. Methods, 2004, 34, 233-239.	1.9	2
45	Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2020, 15, e113-e116.	0.5	2
46	Malignant Mesothelioma: Mechanism of Carcinogenesis. , 2020, , 343-362.		2
47	Malignant Mesothelioma: Mechanism of Carcinogenesis. , 2014, , 299-319.		2
48	Î±1-Proteinase inhibitor is the serum regulator of the activity of p57, a C3-cleaving proteinase present in human erythrocyte membranes. Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1402, 131-138.	1.9	1
49	Asbestos and Mesothelioma: What Is Recent Advance in Research on Asbestos-Induced Molecular Carcinogenesis?. Respiratory Disease Series, 2021, , 17-31.	0.1	1
50	Abstract 112: Genetic alterations in molecular tumor subgroups of malignant pleural mesothelioma. , 2016, , .		1
51	Abstract B14: Discovery of YAP-TEAD protein-protein interaction inhibitors (PPI) for treating malignant pleural mesothelioma (MPM). Molecular Cancer Research, 2020, 18, B14-B14.	1.5	1
52	Expression of anti-cathepsin L ScFv inhibites secretion of procathepsin L, a cysteine proteinase which cleaves human C3, the third component of complement and metastatic phenotype of human melanoma cells. Molecular Immunology, 2007, 44, 3950.	1.0	0
53	Thoracic Neoplasiaâ€“Mesothelioma. , 2014, , 2690-2700.		0
54	ES17.02 Molecular Heterogeneity. Journal of Thoracic Oncology, 2019, 14, S56.	0.5	0

#	Article	IF	Citations
55	Abstract 3128: Spatial intra-tumor molecular heterogeneity in malignant pleural mesothelioma. , 2021, , .		0
56	Abstract 3666: Co-occurring mutations of tumors suppressor genes, NF2 and LATS2, in malignant pleural mesothelioma. , 2016, , .		0